1797P Polo-like Kinase-1 As a Biomarker in Resected Non-Small Cell Lung Cancer

Polo-Like Kinase-1 (PLK1) exerts its influence by affecting the progression of the cell through G2/M checkpoint. Higher levels of PLK1 promote transition of the cell phase to mitosis, thereby promoting cell proliferation. Overexpression of PLK1 mRNA has been shown to be associated with worse clinico-pathological features and patient outcomes in various cancer types, including non-small cell lung cancer (NSCLC). Reports of protein expression of PLK1 by immunohistochemistry in tumour tissue has suggested a similar trend whereby higher expression of PLK1 is associated with aggressive tumour behaviour.